The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022-Reference-Cited by-全球学者库

The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022

Published:2023-09-12 Issue:1 Volume:20 Page:652-694
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Veitch Dallas P.¹²^ORCID,Weiner Michael W.²³⁴⁵⁶,Miller Melanie¹²,Aisen Paul S.⁷,Ashford Miriam A.¹,Beckett Laurel A.⁸,Green Robert C.⁹,Harvey Danielle⁸,Jack Clifford R.¹⁰,Jagust William¹¹,Landau Susan M.¹¹,Morris John C.¹²¹³¹⁴,Nho Kwangsik T.¹⁵¹⁶,Nosheny Rachel²⁵,Okonkwo Ozioma¹⁷,Perrin Richard J.¹²¹³¹⁴,Petersen Ronald C.¹⁸,Rivera Mindt Monica¹⁹²⁰,Saykin Andrew¹⁵²¹,Shaw Leslie M.²²,Toga Arthur W.²³,Tosun Duygu²³,

Affiliation:

1. Department of Veterans Affairs Medical Center Northern California Institute for Research and Education (NCIRE) San Francisco California USA

2. Department of Veterans Affairs Medical Center Center for Imaging of Neurodegenerative Diseases San Francisco California USA

3. Department of Radiology and Biomedical Imaging University of California San Francisco California USA

4. Department of Medicine University of California San Francisco California USA

5. Department of Psychiatry and Behavioral Sciences University of California San Francisco California USA

6. Department of Neurology University of California San Francisco California USA

7. Alzheimer's Therapeutic Research Institute University of Southern California San Diego California USA

8. Division of Biostatistics Department of Public Health Sciences University of California Davis California USA

9. Division of Genetics Department of Medicine Brigham and Women's Hospital Broad Institute Ariadne Labs and Harvard Medical School Boston Massachusetts USA

10. Department of Radiology Mayo Clinic Rochester Minnesota USA

11. Helen Wills Neuroscience Institute University of California Berkeley Berkeley California USA

12. Knight Alzheimer's Disease Research Center Washington University School of Medicine Saint Louis Missouri USA

13. Department of Neurology Washington University School of Medicine Saint Louis Missouri USA

14. Department of Pathology and Immunology Washington University School of Medicine Saint Louis Missouri USA

15. Department of Radiology and Imaging Sciences and the Indiana Alzheimer's Disease Research Center Indiana University School of Medicine Indianapolis Indiana USA

16. Center for Computational Biology and Bioinformatics Indiana University School of Medicine Indianapolis Indiana USA

17. Wisconsin Alzheimer's Disease Research Center and Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

18. Department of Neurology Mayo Clinic Rochester Minnesota USA

19. Department of Psychology Latin American and Latino Studies Institute African and African American Studies Fordham University New York New York USA

20. Department of Neurology Icahn School of Medicine at Mount Sinai New York New York USA

21. Department of Medical and Molecular Genetics Indiana University School of Medicine Indianapolis Indiana USA

22. Department of Pathology and Laboratory Medicine and the PENN Alzheimer's Disease Research Center Center for Neurodegenerative Research Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

23. Laboratory of Neuro Imaging Institute of Neuroimaging and Informatics Keck School of Medicine of University of Southern California Los Angeles California USA

Abstract

AbstractThe Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, and biofluid samples. We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies. This review details how ADNI studies improved disease progression understanding and clinical trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, and modeling improved clinical trials and plasma biomarkers like phosphorylated tau showed promise for clinical use. Biomarkers of amyloid beta, tau, neurodegeneration, inflammation, and others were prognostic with individualized prediction algorithms available online. Studies supported the amyloid cascade, emphasized the importance of neuroinflammation, and detailed widespread heterogeneity in disease, linked to genetic and vascular risk, co‐pathologies, sex, and resilience. Biological subtypes were consistently observed. Generalizability of ADNI results is limited by lack of cohort diversity, an issue ADNI‐4 aims to address by enrolling a diverse cohort.

Funder

National Institutes of Health

National Institute on Aging

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Reference320 articles.

1. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI)

2. The Parkinson Progression Marker Initiative (PPMI)

3. Tau deposition patterns are associated with functional connectivity in primary tauopathies

4. Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease

5. Traumatic brain injury and post‐traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness comparison between blood biomarkers and conventional tests in Alzheimer's disease diagnosis;Drug Discovery Today;2024-02